Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
September 21, 2020
New Scientific Publications
Each week, Fred Hutch librarians search PubMed and Web of Science to discover new papers published by Fred Hutch authors
Week of September 20, 2020
Adoptive transfer of engineered T cells prolongs survival in preclinical ovarian cancer
From the Greenberg lab, Clinical Research Division, and the Vaccine and Infectious Disease Division
Nanoparticles open doors to cancer-fighting CAR T cells
Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy
How does leukemia escape from immunotherapy?
New tech enables deep dive into mysterious results, sets stage for future improvements
When the humanized mice make the MATCH
from the Kiem lab, Clinical Research Division
Fred Hutch research to be presented at American Society of Hematology conference
Fred Hutch researchers to share latest research in immunotherapy, genetic markers, graft vs. host disease, cord blood and more
Good News: Malik and Bloom win ASM awards; pilot project funded by Bezos family aims to create personalized anticancer vaccines
Celebrating faculty and staff achievements
New clues to treating deadly skin cancer
Small clinical trial finds two forms of immunotherapy may be better than one for treating metastatic melanoma
Got ideas for better, faster cancer cures?
After Vice President Joe Biden’s Fred Hutch visit, we ask panelists for their ‘moonshot’ wish lists
10 years to cancer cures 'actually plausible,' Fred Hutch president says
'We are on the threshold of amazing advances,' Dr. D. Gary Gilliland tells industry, research leaders
International research team discovers genes and disease mechanisms behind a common form of muscular dystrophy
Discovery could lead to a biomarker-based test for diagnosis
Center awarded $11.5 million for breast cancer research consortium
Porter, Cheever will lead the five-year Seattle-based SPORE in projects including development of targeted treatments for drug-resistant tumors